Copyright
©The Author(s) 2025.
World J Gastroenterol. Jun 7, 2025; 31(21): 106939
Published online Jun 7, 2025. doi: 10.3748/wjg.v31.i21.106939
Published online Jun 7, 2025. doi: 10.3748/wjg.v31.i21.106939
Table 3 Univariate and multivariate Cox analysis of the effect of prognostic factors in the original cohort, n (%)
Dependent: Survival (PFS/30, status) | All patients (n = 131) | HR (univariable) | HR (multivariable) | |
Gender | Male | 76 (58.0) | - | - |
Female | 55 (42.0) | 0.87 (0.60-1.26, P = 0.458) | - | |
Age | > 60 | 66 (50.4) | - | - |
≤ 60 | 65 (49.6) | 0.73 (0.50-1.07, P = 0.110) | - | |
ECOG | 0-1 | 116 (88.5) | - | - |
2 | 15 (11.5) | 1.34 (0.73-2.47, P = 0.340) | - | |
Number of metastatic organs | 1 | 55 (42.0) | - | - |
≥ 2 | 76 (58.0) | 1.96 (1.32-2.90, P < 0.001) | 1.90 (1.27-2.84, P = 0.002) | |
Primary tumor location | Right colon | 32 (24.4) | - | - |
Left colon and rectum | 99 (75.6) | 0.92 (0.61-1.40, P = 0.697) | - | |
Liver metastasis | No | 46 (35.1) | - | - |
Yes | 85 (64.9) | 1.57 (1.04-2.36, P = 0.032) | 1.28 (0.84-1.96, P = 0.254) | |
Lung metastasis | No | 70 (53.4) | - | - |
Yes | 61 (46.6) | 1.23 (0.85-1.78, P = 0.274) | - | |
RAS mutation type | Unknown | 25 (19.1) | - | - |
Wild type | 20 (15.3) | 0.97 (0.51-1.85, P = 0.930) | - | |
Mutation | 86 (65.6) | 1.37 (0.84-2.24, P = 0.202) | - | |
Group | Control group | 105 (80.2) | - | - |
Experimental group | 26 (19.8) | 0.51 (0.31-0.82, P = 0.006) | 0.49 (0.30-0.80, P = 0.004) |
- Citation: Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer. World J Gastroenterol 2025; 31(21): 106939
- URL: https://www.wjgnet.com/1007-9327/full/v31/i21/106939.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i21.106939